Riskpilot← Back to searchSign inGet full accessAfyx Development A/S
A/SActiveCVR 35839739Slotsmarken 11Research and experimental development on natural sciences and engineering · NACE 7210Est. 20141 employeeswww.afyxtx.com
Revenue 2024
DKK -8,4M
+79% vs 2023
EBITDA margin
103.6%
+20% vs 2023
Equity ratio
-94.3%
Financial strength
Net profit 2024
DKK -6,9M
+31% vs 2023
| Revenue | DKK -8,4M | +79% |
| EBITDA | DKK -8,7M | +20% |
| Net profit | DKK -6,9M | +31% |
| Total assets | DKK 3,2M | -30% |
| Equity | DKK -3M | -225% |
| Employees | 1 | — |
Legal name
Afyx Development A/S
CVR number
35839739
Legal form
Aktieselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
30. april 2014
Share capital
DKK 1.000.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede bestyrelse eller af Selskabets administrerende direktør og et medlem af bestyrelsen i forening.
Company purpose
Selskabets formål er at drive forskning og udvikling rettet mod fremstilling og kommercialisering af lægemidler og medicinsk udstyr og andre hermed relaterede aktiviteter.
Address
Slotsmarken 11
Email
info@afyxtx.com
Website
www.afyxtx.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -434 | -1.791 | -10.106 | -23.388 | -37.626 | -52.476 | -36.231 | -27.442 | -8.601 | -4.708 | -8.424 |
| Staff expenses | -0 | -0 | -1.153 | -5.106 | -13.062 | -10.331 | -9.098 | -6.477 | -4.433 | -6.196 | -302 |
| EBITDA | -434 | -1.791 | -11.259 | -28.494 | -50.688 | -62.807 | -45.329 | -33.919 | -13.034 | -10.904 | -8.726 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -395 | -499 | -499 | -499 | -499 | -105 | -0 |
| EBIT | -434 | -1.791 | -11.259 | -28.494 | -51.083 | -63.306 | -45.828 | -34.418 | -13.534 | -11.009 | -8.726 |
| Net financials | -5 | -50 | -79 | -2.339 | 446 | 69 | -9.151 | -5.912 | -11.891 | 70 | -116 |
| Profit before tax | -439 | -1.840 | -11.338 | -30.834 | -50.637 | -63.237 | -54.979 | -40.330 | -25.424 | -10.939 | -8.842 |
| Tax | -59 | -371 | -2.080 | -5.268 | -5.582 | -5.500 | -5.500 | -5.280 | -1.149 | -948 | -1.945 |
| Net profit | -380 | -1.470 | -9.258 | -25.565 | -45.055 | -57.737 | -49.479 | -35.050 | -24.275 | -9.991 | -6.896 |
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 113 | 12.631 | 8.092 | 103.485 | 62.161 | 51.457 | 47.819 | 28.458 | 16.264 | 4.511 | 3.175 |
| Equity | -321 | 11.614 | 6.358 | 99.287 | 54.232 | -3.505 | -52.984 | -88.034 | -112.309 | 2.403 | -2.994 |
| Long-term debt | 357 | 764 | 825 | 0 | 0 | 341 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 77 | 253 | 909 | 4.198 | 7.930 | 54.622 | 100.803 | 116.492 | 128.573 | 2.109 | 6.169 |
| Total debt | 434 | 1.016 | 1.734 | 4.198 | 7.930 | 54.962 | 100.803 | 116.492 | 128.573 | 2.109 | 6.169 |
EBITDA margin
-872608600.0%
This company
15.8%
Market median
-5522839341% vs market
20142024
Equity ratio
-94.3%
This company
38.2%
Market median
-347% vs market
20142024
Return on equity
-689649000.0%
This company
18.4%
Market median
-3748092491% vs market
20142024
Net profit margin
-689649000.0%
This company
8.1%
Market median
-8514185285% vs market
20142024
Asset turnover
-2.65×
This company
1.12×
Market median
-337% vs market
20142024
Debt / equity
2.06×
This company
0.62×
Market median
-232% vs market
20142024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-04-30 – 2014-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LS Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
Nd Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
JH Chief Executive Officer | Chief Executive Officer | 2014 | — | — |
CJ Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2015 | — | — | |
| Chairman | 2017 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2015 | — | — | |
| Board of Directors | 2015 | — | — | |
| Chairman | 2015 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Afyx Therapeutics A/S | Company | 100.0% | 100.0% | 2024 |
| Individual | 5.0% | 5.0% | 2015 | |
Novo Holdings A/S | Company | 10.0% | 10.0% | 2017 |
JEGUBALCO ApS | Company | 5.0% | 5.0% | 2017 |
| Individual | 5.0% | 5.0% | 2016 | |
HELLERUNG ApS | Company | 5.0% | 5.0% | 2017 |
| Individual | 33.3% | 33.3% | 2017 | |
FONDEN FOR SYDDANSK VÆKSTFREMME | Company | 5.0% | 5.0% | 2015 |
VIRKSOMHEDSPARTNER ApS | Company | 10.0% | 10.0% | 2015 |
SPOGÁRD HOLDING ApS | Company | 5.0% | 5.0% | 2015 |
| Individual | 0.0% | 5.0% | 2015 | |
LUNDBECKFOND INVEST A/S | Company | 10.0% | 10.0% | 2017 |
| Individual | 25.0% | 25.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Afyx Capital ApS
Afyx Development A/S Board members of Afyx Development A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Siim Madsen | Chief Executive Officer | 0 companies |
| Nishan de Silva | Chief Executive Officer | 0 companies |
| Jens Hansen | Chief Executive Officer | 0 companies |
| Claus Juan Møller-San Pedro | Chief Executive Officer | 0 companies |
| Kristine Peterson | Board of Directors | 0 companies |
| Mads Spangaard Rasmussen | Board of Directors | 0 companies |
| Lars Gosta Ekman | Chairman | 0 companies |
| Ole Baadsgaard | Chairman | 0 companies |
| Pia Leah Møller-San Pedro | Board of Directors | 0 companies |
| Søren Mohrsen Kjær | Board of Directors | 0 companies |
| Stephan Christgau | Board of Directors | 0 companies |
| Christian Ellebæk Elling | Board of Directors | 0 companies |
| Morten Aleksandr Engel | Board of Directors | 0 companies |
| René Jørgen Spogard | Board of Directors | 0 companies |
| Keld Aage Søndergaard | Board of Directors | 0 companies |
| Hans Anders Åkerlund | Chairman | 0 companies |